컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American Thoracic Society International Conference 2025 (ATS 2025)

16 May - 21 May, 2025, United States

BGF initiation after an exacerbation in COPD: Does timing matter?

2025-09-16

Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).
Bispecific antibody overcomes P. aeruginosa infection in patients with bronchiectasis

2025-09-16

The bispecific antibody gremubamab, which targets two proteins on the surface of Pseudomonas aeruginosa, has been shown to substantially reduce bacterial load and improve quality of life for infected bronchiectasis patients in the phase II GREAT-2 study.
COPD detection refined with new diagnostic schema

2025-09-16

Incorporating spirometry with respiratory symptoms and quality of life and structural lung abnormalities on CT imaging to meet criteria for a chronic obstructive pulmonary disease (COPD) diagnosis spots additional patients at risk of poor respiratory outcomes, according to the results of a study presented at the ATS annual meeting and simultaneously published in JAMA.
Digital therapy improves life quality of patients with pulmonary fibrosis

2025-09-16

A novel digital psychological therapy, named Almee, demonstrates efficacy in improving health-related quality of life (HRQOL) in patients with pulmonary fibrosis, irrespective of antifibrotic treatment use, reports a study presented at ATS 2025.
Methotrexate on par with prednisone as first-line treatment for pulmonary sarcoidosis

2025-09-16

The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.
Nerandomilast slows IPF progression in patients already on antifibrotic therapy

2025-09-16

The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.
WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

2025-09-16

Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브